4'-DiMethylaMino 7,8-Dihydroxyflavone HydrobroMide:Exports & Compliance White Paper 2026

I. Executive Summary

4'-Dimethylamino-7,8-dihydroxyflavone hydrobromide (CAS 1205548-00-0) is a synthetically modified flavone supplied exclusively as a research-grade compound. It must be stated plainly at the outset: the substance has no approved therapeutic indication in any jurisdiction, is not a drug, is not a finished consumer or dietary product, and is not for human or veterinary use. Commercial activity around it is therefore correctly framed as a contract development and manufacturing organisation proposition: custom synthesis, process research and development, analytical method development and validation, and controlled supply of Research Use Only material to qualified institutional and industrial laboratories.

The commercial characteristics are the opposite of a bulk intermediate. Volumes are measured in grams to low kilograms, value per gram is high, and the purchase decision is driven by analytical depth, documentation quality and delivery reliability rather than by unit price. Customers are discovery biotech companies, contract research organisations, academic and translational research institutes, and reference-standard or reagent distributors. Each wants the same three things: a defensible identity and purity dataset, a stability story for a notoriously oxidation-prone catechol, and a supplier that will not create regulatory or reputational exposure.

This white paper analyses the molecule from a CDMO and sourcing perspective: structural features that create both scientific interest and handling difficulty, route-class chemistry and purification strategy, the analytical and quality-system package required at research and GMP levels, containment practice derived from health-based exposure limits, cold-chain logistics, and the know-your-customer and end-use-declaration controls that govern lawful supply. It contains no dosing information, no health, nootropic or performance claims and no consumer framing.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The compound is a 2-phenylchromen-4-one flavone bearing a catechol at the 7,8-positions, a para-dimethylamino substituent on the pendant phenyl ring, and a hydrobromide salt form. The free base has a molecular weight in the high two hundreds, with the bromide counter-ion lifting the salt form into the high three hundreds. It is a coloured crystalline to amorphous solid, readily soluble in dimethyl sulfoxide, dimethylformamide and similar polar aprotic solvents and only sparingly soluble in water, and the dimethylamino group confers pH-dependent spectroscopic behaviour that analysts exploit for detection.

• Catechol Oxidation Liability: The adjacent 7,8-dihydroxy arrangement is the defining stability constraint. Under neutral to alkaline pH, in the presence of dissolved oxygen, trace metal ions or light, the catechol oxidises to semiquinone and quinone species that polymerise into coloured degradation products. This drives inert-atmosphere handling, amber packaging, low-temperature storage and control of trace metals in excipients and solvents.
• Research-Tool Function and Counter-Ion Effects: The compound is used strictly as a non-clinical research probe for receptor-signalling investigations in biochemical and cell-based systems. Salt form matters: hydrobromide improves crystallinity, handling and weighed-dose accuracy relative to the free base, but introduces a bromide stoichiometry and bromide-content assay requirement that must be specified and certified.

2.2 Synthesis and Manufacturing Technologies

Consistent with legitimate CDMO practice, this document discusses chemistry only at the route-class level. The flavone core is conventionally assembled from appropriately substituted acetophenone and benzoic-acid-derived building blocks through a beta-diketone intermediate and cyclodehydration, or through chalcone intermediates cyclised oxidatively, followed by salt formation with hydrobromic acid. Commercial differentiation arises from purification strategy, polymorphic and salt-form control, containment engineering and the analytical package rather than from disclosure of operating detail.

• Purification and Salt-Form Control: Chromatographic polishing, controlled precipitation or crystallisation, and rigorous removal of metal catalysts, residual reagents and regioisomeric byproducts determine whether a batch meets a research specification. Salt stoichiometry, residual bromide, polymorphic form, particle characteristics and residual solvent profile must all be controlled and documented, not merely assayed at the end.
• Containment and Quality-System Design: Because no established occupational exposure limit exists, responsible manufacturers derive a health-based exposure limit and assign an occupational exposure band, then engineer to that band with isolator or glove-box handling, HEPA filtration, dedicated cleaning validation and campaign-based manufacturing. ICH Q7 and Q11 principles are applied to GMP campaigns even when the immediate delivery is research grade.

2.3 Core Application Matrix

• Non-Clinical Research Probe: Purchased by discovery organisations for in vitro biochemical and cell-based assays investigating receptor-mediated signalling pathways. Supplied as Research Use Only material with documented identity and purity; no therapeutic, diagnostic or human-use claim is made or implied.
• Analytical Reference Standard: Used by laboratories developing and validating quantitative methods, impurity profiling or stability-indicating assays, where a well-characterised lot with full chromatographic and spectroscopic documentation is the deliverable.
• Custom Synthesis and Process Development Platform: Engaged by clients as a model substrate for route scouting, impurity identification, polymorph screening and scale-up studies under confidential technology-transfer agreements ahead of any regulated campaign.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is research-budget driven rather than industrially driven. Funding cycles in neuroscience-adjacent discovery, the outsourcing of chemistry to CROs and CDMOs, and the growth of small virtual biotech companies with no internal laboratories all expand the addressable market. Because these customers buy small quantities repeatedly across many projects, their loyalty follows documentation quality and responsiveness: a supplier that delivers a complete analytical dossier and a reliable cold chain wins the next project almost automatically.

3.2 Capacity Distribution and Export Flows

Capacity is distributed among Asian custom-synthesis houses, Indian integrated CDMOs and a smaller set of Western research-reagent specialists and GMP-capable facilities. Chinese producers in the Yangtze River Delta and around Shanghai and Suzhou dominate early-stage custom synthesis on cost and speed; Indian CDMOs in Hyderabad, Bengaluru and Gujarat combine route development with GMP capability and English-language regulatory documentation; US and European suppliers retain share in reference standards, GMP campaigns and customers requiring domestic supply and audit access.

3.3 Market Bifurcation and Pricing Dynamics

The market is sharply bifurcated. Catalog-grade research material is priced per milligram or per gram with a generic certificate of analysis, while custom-synthesised, fully characterised batches and GMP campaigns are priced per campaign with milestone payments, analytical development charges and stability commitments. The premium reflects analytical labour, containment cost, cold-chain logistics and intellectual-property confidentiality obligations rather than raw material cost, and buyers who benchmark against catalog prices misunderstand what they are purchasing.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Compliance for this compound is not about a single registration; it is about positioning. The supplier must be unambiguous that the material is Research Use Only, that no approved therapeutic indication exists, and that the substance is not offered for human or veterinary use or as a finished consumer or dietary product. Every downstream obligation follows from that positioning, and any ambiguity in quotations, catalogue copy or labels creates real legal exposure for both parties.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Status and Research-Quantity Supply: Supply into the EU at research volumes is normally handled under the registration regime applicable to the placed tonnage, with scientific research and development and product and process oriented research and development provisions where the conditions are genuinely met. Suppliers should not assume an exemption: eligibility must be assessed per customer, per quantity and per use, and documented before dispatch.
• CLP, SDS and GMP Chain Obligations: Classification, labelling and safety data sheet provision follow normal hazard-assessment rules, and any material intended for a regulated clinical campaign must transition into the EU good manufacturing practice framework with appropriate active-substance documentation, qualified person release and an authorised supply chain.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Status and Research-Use Positioning: Commercial supply requires clarity on inventory status and on the applicability of research and development or low-volume provisions, verified for the specific substance identity and the specific customer use. Importers and distributors should retain that determination in the commercial file rather than relying on a supplier's verbal assurance.
• FDA Boundary: RUO Material versus Clinical Material: The compound has no approved therapeutic indication and is not a lawful dietary or consumer ingredient. Material used in human investigations would have to be produced under good manufacturing practice and supplied within an authorised investigational framework; research-grade material must never be presented, labelled or documented in a way that invites human administration.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

ESG expectations for research-grade custom synthesis are set by the customer's own investor and procurement policies rather than by carbon tariffs, because the volumes are too small for direct climate regulation. Even so, solvent footprint and waste treatment are visible in audits, and a documented position is now expected in every serious CDMO tender.

5.1 Carbon Footprint and Circular Economy

Environmental load is dominated by chromatographic solvent consumption, energy for low-temperature and inert-atmosphere operations, and cold-chain distribution rather than by the synthesis itself. Responsible CDMOs report Scope 1 and Scope 2 data, recover solvents where specification permits, and evaluate Scope 3 categories covering purchased reagents, waste treatment and refrigerated transport. Circularity claims should be modest and factual, focused on solvent recovery rates, energy per campaign and reduction of re-synthesis through right-first-time analytical release.

5.2 Sustainable Sourcing and Traceability

Traceability means complete batch genealogy: starting-material lots, reagent certificates, process records, in-process controls, analytical raw data, reference-standard provenance and distribution records, retained for the customer's project lifetime. ISO 9001 is the quality baseline, ISO 14001 and ISO 45001 support environmental and occupational claims, and confidentiality controls protecting the client's structure, route and data are treated as a compliance deliverable in their own right.

VI. Supply Chain Resilience and Export Logistics

Logistics are governed by one chemistry fact: the catechol oxidises. Every packaging and transit decision therefore aims to exclude oxygen, light, heat and moisture. A batch released at high purity can arrive visibly degraded if packed under air in clear glass and shipped without temperature control, and degradation disputes are among the most common commercial failures in this product class.

6.1 Packaging Standards and Moisture/Contamination Control

• Amber Glass, Inert Headspace and Desiccation: Material is packed in amber glass vials or bottles with inert-gas headspace, moisture barrier closures and desiccant where specified, then sealed in secondary barrier packaging. Headspace oxygen should be verified rather than assumed, and pack-level appearance recorded before dispatch.
• Trace-Metal-Free Contact Materials: Contact surfaces, septa and closures are selected to avoid metal ion contamination that catalyses catechol oxidation, and vial caps are qualified for low extractables. For GMP material, packaging components require their own specification, certificates and, where appropriate, extractables and leachables assessment.

6.2 Dangerous Goods Identification and Transit Protocols

Many research-grade flavone salts are shipped as non-regulated goods, but classification must always be confirmed against the current safety data sheet and modal regulations for the specific lot rather than assumed from precedent. Where a hazard classification applies, ADR, IMDG and IATA provisions govern packaging, marking, labelling and documentation. Cold-chain transit typically uses refrigerated or frozen shipment with dry ice or gel packs, continuous temperature logging, validated insulated shippers and predefined excursion handling. Customs clearance is smoother when the accompanying documentation states the research-use status, the end-use declaration reference and the consignee's institutional identity.

VII. Enterprise Global Expansion Strategy Guide

Growth in this segment comes from becoming the partner a research organisation trusts with its next molecule. The following sequence reflects how CDMOs actually win and retain research and development accounts.

1. Institutionalise RUO Positioning and KYC: Apply Research Use Only labelling, explicit no-approved-therapeutic-indication and not-for-human-or-veterinary-use statements, end-use declarations and screening against applicable controlled-substance, sanctions and anti-doping lists on every order. Refuse orders lacking institutional identity or a coherent research rationale, and document the refusal.
2. Productise the Analytical Package: Offer defined tiers: research grade with orthogonal identity and validated purity, characterised grade with full impurity profiling and stability data, and GMP grade under ICH Q7 and Q11 with qualified-person release. Publish the method list, acceptance criteria and deliverables so quoting is fast and defensible.
3. Build Technology Transfer and Confidentiality Capability: Invest in secure data rooms, segregated project teams, clean-room documentation and rapid tech-transfer protocols. Clients choose on trust: the perception that a structure and route will not leak is often worth more than a lower quotation.

VIII. Conclusion

4'-Dimethylamino-7,8-dihydroxyflavone hydrobromide should be approached as a research compounds business, not as a chemicals trading opportunity. It has no approved therapeutic indication, is not for human or veterinary use, and is not a finished consumer or dietary product. Within that boundary there is genuine, legitimate commercial activity: custom synthesis, process development, analytical method development and validation, and tightly controlled Research Use Only supply.

The suppliers that succeed are those that treat documentation, containment, cold chain and confidentiality as the product. Oxidation-prone catechol chemistry punishes casual handling, incomplete analytics punish weak quality systems, and ambiguous positioning punishes everyone in the chain. A CDMO that can deliver orthogonal identity confirmation, a validated stability-indicating method, health-based containment, reliable refrigerated logistics and rigorous know-your-customer control will remain the supplier of choice as research demand for complex flavone derivatives continues to evolve.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 4'-Dimethylamino-7,8-dihydroxyflavone hydrobromide Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 4'-Dimethylamino-7,8-dihydroxyflavone hydrobromide supply chain:

• China Custom Synthesis Cluster: Yangtze River Delta and Shanghai and Suzhou laboratories provide fast route scouting and small-batch custom synthesis with cost-competitive analytical support.
• India CDMO Corridor: Hyderabad, Bengaluru and Gujarat organisations combine process research, GMP capability and English-language regulatory documentation for Western biotech clients.
• US and EU Reagent and GMP Network: Research reagent distributors, reference-standard producers and GMP-capable facilities supply domestic customers requiring audit access, cold-chain speed and regulated documentation.